Drug Trial Radar · NCT01877954
Qvar vs FP in Pediatrics
Last checked: Nov 19, 2026Latest source record: Jun 14, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,654
Actual
Start
Feb 2011
Primary completion
Mar 2013
Study completion Mar 2013
Sponsor
- Lead sponsor
- Research in Real-Life LtdResearch network
- Sponsor type
- Research network
- Collaborators
- Teva Branded Pharmaceutical Products R&D, Inc.
- First posted
- Jun 14, 2013
Design
- Study type
- Observational
- Who can join
- All sexes, from 5 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary aim of this study was to compare the absolute and relative effectiveness of asthma management in paediatric patients in the UK on inhaled corticosteroid (ICS) maintenance therapy as extra-fine HFA-BDP (Qvar®) pressurised metered dose inhaler (pMDI) compared with fluticasone propionate (FP) pMDI.
Conditions
- Asthma
Interventions
Extra-fine hydrofluoroalkane beclometasone dipropionateDrug
Fluticasone propionateDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proxy risk domain asthma controlTime frame: One year outcome period
- Asthma exacerbation rate ratioTime frame: One year outcome period
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.